interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development
EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
Clinical Trials Information System (CTIS).
The EU Clinical Trials Register currently displays
44334
clinical trials with a EudraCT protocol, of which
7366
are clinical trials conducted with subjects less than 18 years old.
The register also displays information on
18700
older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).
Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see
Frequently Asked Questions ).
5 result(s) found for: UCP2.
Displaying page 1 of 1.
EudraCT Number: 2018-002279-16
Sponsor Protocol Number: EOGBM1-18
Start Date*: 2020-01-02
Sponsor Name:Enterome
Full Title: A MulticenteR, Open-Label, First-in-Human, PhaSe Ib/IIa Trial of EO2401, a Novel Multipeptide Therapeutic VAccine, with and without PD-1 Check Point Inhibitor, FoLlowing Standard Treatment in PatIe...
Medical condition: Progressive or recurrent Glioblastoma (PG)
Disease:
Version
SOC Term
Classification Code
Term
Level
20.0
10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Full Title: A phase 1/2 trial of EO2401, a novel microbial-derived peptide therapeutic vaccine, in combination with PD-1 check point blockade, for treatment of
patients with locally advanced or metastatic adr...
Medical condition: - locally advanced or metastatic adrenocortical carcinoma (ACC)
- malignant pheochromocytoma/paraganglioma (MPP)
Disease:
Version
SOC Term
Classification Code
Term
Level
20.0
10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)
10001388
Adrenocortical carcinoma
PT
20.1
10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)
10034876
Pheochromocytoma
LLT
20.0
10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Full Title: A global multicenter phase 1/2 trial of EO4010, a novel microbial-derived peptide therapeutic vaccine, in combination with nivolumab, for treatment of patients with previously treated metastatic co...
Medical condition: Patients with unresectable, previously treated locally advanced or metastatic colorectal carcinoma.
Disease:
Version
SOC Term
Classification Code
Term
Level
21.0
10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)
10061451
Colorectal cancer
PT
21.0
10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)
10052358
Colorectal cancer metastatic
PT
20.0
10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)
10010036
Colorectal carcinoma
LLT
21.0
10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)
10052362
Metastatic colorectal cancer
LLT
Population Age: Adults, Elderly
Gender: Male, Female
Trial protocol:FR(Trial now transitioned)ES(Ongoing)
Trial results:(No results available)
EudraCT Number: 2020-003999-40
Sponsor Protocol Number: EONHL1-20
Start Date*: 2021-02-09
Sponsor Name:Enterome
Full Title: A global multicenter phase 1/2 trial of EO2463, a novel microbial-derived peptide therapeutic vaccine, as monotherapy, and in combination with lenalidomide and rituximab, for treatment of patients ...
Medical condition: Indolent Non-Hodgkin's Lymphoma (Follicular Lymphoma; Marginal Zone Lymphoma)
Disease:
Version
SOC Term
Classification Code
Term
Level
22.0
10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)
10029547
Non-Hodgkin's lymphoma
PT
Population Age: Adults, Elderly
Gender: Male, Female
Trial protocol:FR(Trial now transitioned)IT(Trial now transitioned)
Trial results:(No results available)
EudraCT Number: 2022-002679-12
Sponsor Protocol Number: EOCRC1-22
Start Date*: 2023-06-01
Sponsor Name:Enterome SA
Full Title: A phase 2 trial of EO2040, a miCrobiaL-derived peptide therApeUtic vaccine, in combination with nivolumab, for treatment of patients with circulating tumor DNA-dEfined minimal residual disease of c...
Medical condition: Patients with circulating tumor DNA-defined minimal residual disease of colorectal cancer stage II, III, or IV after completion of curative therapy .
Disease:
Version
SOC Term
Classification Code
Term
Level
21.0
10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)
10061451
Colorectal cancer
PT
21.0
10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)
10010033
Colorectal cancer stage II
PT
21.0
10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)
10010034
Colorectal cancer stage III
PT
21.0
10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Subscribe to this Search
To subscribe to the RSS feed for this search click
here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
Download Options:
Number of Trials to download:
Download Content:
Download Format:
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
• EEA CTAs: Date study was authorised to proceed • Outside EU/EEA: Date study was submitted in EudraCT